Semagacestat doesn't improve cognitive status in Alzheimer's

July 25, 2013
Semagacestat doesn't improve cognitive status in alzheimer's
For patients with Alzheimer's disease, treatment with the small-molecule γ-secretase inhibitor semagacestat does not improve cognitive status and is associated with worsening of cognitive function, according to a study published in the July 25 issue of the New England Journal of Medicine.

(HealthDay)—For patients with Alzheimer's disease, treatment with the small-molecule γ-secretase inhibitor semagacestat does not improve cognitive status and is associated with worsening of cognitive function, according to a study published in the July 25 issue of the New England Journal of Medicine.

Rachelle S. Doody, M.D., Ph.D., from the Baylor College of Medicine in Houston, and colleagues randomized 1,537 patients with probable Alzheimer's disease to receive 100 mg semagacestat, 140 mg semagacestat, or placebo daily in a double-blind trial. Changes in cognition were assessed from baseline to week 76 using the cognitive subscale of the Alzheimer's Disease Assessment Scale for cognition (ADAS-cog), and changes in functioning were measured using the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale.

Based on the recommendation of the data and safety monitoring board, the trial was terminated before completion, when there were 189 patients in the and 153 and 121 in the 100 mg and 140 mg semagacestat groups, respectively. The researchers found that the ADAS-cog scores worsened in all groups, with no significant differences noted between the study drug and placebo arms. In all groups, the ADCS-ADL scores worsened (P = 0.14 for placebo versus 100 mg semagacestat; P < 0.001 for placebo versus 140 mg semagacestat). Treatment with semagacestat correlated with significantly more weight loss, skin cancers and infections, adverse event related treatment discontinuation, and serious adverse events.

"As compared with , semagacestat did not improve , and patients receiving the higher dose had significant worsening of functional ability," the authors write. "Semagacestat was associated with more adverse events, including skin cancers and infections."

The study was funded by Eli Lilly.

More information: Full Text (subscription or payment may be required)

Related Stories

Donepezil found helpful in dementia with lewy bodies

July 31, 2012

(HealthDay) -- For patients with dementia with Lewy bodies (DLB), treatment with 5 or 10 mg/day donepezil is associated with significant cognitive, behavioral, and global function improvements, according to research published ...

Tadalafil effective, safe in complete erectile dysfunction

October 14, 2012

(HealthDay)—In men with complete erectile dysfunction (ED), tadalafil 2.5 and 5 mg once-daily result an in intercourse success rate of 32.4 and 46.4 percent, respectively, according to research published online Oct. 4 in ...

Latrepirdine not effective in Huntington's disease

November 1, 2012

(HealthDay)—Although safe and well tolerated, the experimental small molecule latrepirdine does not improve cognition after six months of treatment in patients with mild-to-moderate Huntington's disease (HD), according ...

Recommended for you

Insulin's potential to treat dementia outlined in new study

August 4, 2015

Researchers at the UW Medicine, Veteran's Administration Puget Sound and Saint Louis University have made a promising discovery that insulin delivered high up in the nasal cavity goes to affected areas of brain with lasting ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.